SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.

The Nuclear Regulatory Commission has approved a request by SHINE Medical Technologies for an exemption from regulations on how commercial grade equipment is defined, allowing the company to more easily procure components for the medical isotope production facility it is building in Janesville, Wis.

Completing a 5,700-mile journey from Belgium, two 24-ton particle accelerators were delivered to NorthStar Medical Radioisotopes’ facility in Beloit, Wis., on April 22, the Wisconsin State Journal reported. Photos and a video of the accelerators being received at the facility are included in the report.

Darlington nuclear generating station. Photo: OPG

Ontario Power Generation, its subsidiary Laurentis Energy Partners, and BWXT ITG Canada and its affiliates announced on September 24 that the companies are making “significant progress” toward the production of molybdenum-99 at OPG’s Darlington nuclear power plant. Darlington will become the first commercial operating nuclear reactor to produce the medical radioisotope.

A precursor to technetium-99m, Mo-99 is used in more than 40 million procedures a year to detect cancers and diagnose various medical conditions.

Shine Medical Technologies, which is building a medical isotope production facility in Janesville, Wis., said on May 11 that it expects to have an operating license issued by the Nuclear Regulatory Commission by October 2021. Shine’s application seeking approval to operate the facility, which will produce isotopes including molybdenum-99, was accepted and docketed by the NRC last October. Mo-99, the precursor to technetium-99m, is used in more than 40 million medical patient procedures every year.

Belgium’s National Institute of Radioelements (IRE) announced on April 30 that it has produced its first batch of commercial molybdenum-99 from low-enriched uranium (LEU) targets. The first batch of Mo-99, whose decay product, technetium-99m, is used in nuclear medicine for diagnostic imaging, was produced for the U.S. health market. IRE said that the conversion to LEU represents a key milestone for the institute in the global commitment to end the civilian use of highly enriched uranium (HEU) for the production of Mo-99.

The U.S. healthcare industry is warning that the COVID-19 pandemic may threaten supplies of the medical radioisotope molybdenum-99, whose decay product, technetium-99m, is considered the workhorse isotope in nuclear medicine for diagnostic imaging. The online magazine Radiology Business recently reported that the American Society of Nuclear Cardiology (ASNC) alerted its members on April 1 that it is monitoring supply shortages of Mo-99 “more closely than ever” during the pandemic.